Atlanta, GA, United States
Atlanta, GA, United States

Emory University is a private research university in metropolitan Atlanta, located in the Druid Hills section of unincorporated DeKalb County, Georgia, United States. The university was founded as Emory College in 1836 in Oxford, Georgia by the Methodist Episcopal Church and was named in honor of Methodist bishop John Emory. In 1915 the college relocated to metropolitan Atlanta and was rechartered as Emory University.Emory University has nine academic divisions: Emory College of Arts and science, Oxford College, Goizueta Business School, Laney Graduate School, School of Law, School of Medicine, Nell Hodgson Woodruff School of Nursing, Rollins School of Public Health, and the Candler School of Theology. Emory University and the Georgia Institute of Technology have a strong research partnership and jointly administer the Emory-Georgia Tech Predictive Health Institute and the Wallace H. Coulter Department of Biomedical Engineering Program with Peking University in Beijing, China. Emory University and the Georgia Institute of Technology's combined annual research expenditures exceed $1.25 billion.Emory University is 16th among the list of colleges and universities in the United States by endowment, 5th among universities in the United States regarding licensing revenue per dollars spent on research, and 21st in U.S. News & World Report's 2015 National Universities Rankings. The university also ranks as one of the top universities in the world. In 1995 Emory University was elected to the Association of American Universities, an association of the 62 leading research universities in the United States & Canada.The university has nearly 3,000 faculty members; Emory faculty and alumni include international leaders in the fields of politics, business and academia, and its members have been recognized with numerous national and international awards and honors. Wikipedia.


Time filter

Source Type

Patent
Dana-Farber Cancer Institute and Emory University | Date: 2017-02-22

The present invention is based, in part, on the identification of novel human anti-PD-1, PD-L1, and PD-L2 antibodies. Accordingly, the invention relates to compositions and methods for diagnosing, prognosing, and treating conditions that would benefit from modulating PD-1, PD-L1, and/or PD-L2 activity (e.g., persistent infectious diseases, autoimmune diseases, asthma, transplant rejection, inflammatory disorders and tumors) using the novel human anti-PD-1, PD-L1, and PD-L2 antibodies described herein.


Patent
Dana-Farber Cancer Institute, Brigham, Women's Hospital, Emory University and The President And Fellows Of Harvard College | Date: 2017-02-15

The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.


Patent
Cocrystal Pharma Inc. and Emory University | Date: 2017-02-22

The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.


Patent
Emory University and Georgia Institute of Technology | Date: 2017-01-20

This disclosure relates to self-assembling peptides that form hydrogels comprising peptide sequences for the activation of signaling pathways. In certain embodiments, the disclosure relates to compositions comprising a recombinant polypeptide comprising a cell signaling sequence, e.g., JAG-1 sequence, fused to a hydrogel polypeptide sequence. In certain embodiments, the disclosure relates to methods of cell culture on three dimensional scaffolds/hydrogels composed of self-assembling peptides disclosed herein.


Patent
Cocrystal Pharma Inc. and Emory University | Date: 2017-03-01

The present invention is directed to compounds, compositions and methods for treating or preventing Flaviviridae family of viruses (including HCV, Yellow fever, Dengue, Chikungunya and West Nile virus), RSV and influenza infection and cancer in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.


The disclosure relates to Prostaglandin receptor EP2 antagonists, derivatives, compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing conditions and diseases in which EP2 receptor activation has a physiological role, such as but not limited to, brain injury, inflammatory diseases, neuroinflamation after a seizure, pain, endometriosis, cancer, rheumatoid arthritis, skin inflammation, vascular inflammation, colitis, and neurological disorders by administering a pharmaceutical composition comprising a compound disclosed herein to a subject in need thereof.


This disclosure relates to compounds, compositions and methods of epigenetically transforming cells. In certain embodiments, the disclosure relates to methods of generating epigenetically altered cells comprising mixing isolated cells with compositions disclosed herein under conditions such that epigenetically altered cells are formed. In certain embodiments, methods of treating or preventing vascular or diabetic diseases or conditions are contemplated. In certain embodiments, epigenetically reprogramming adult bone marrow-derived stem or progenitor cells including mesenchymal stem cells (MSCs) or endothelial progenitor cells (EPCs) for autologous treatments are contemplated.


In certain embodiments, the disclosure relates to heterocyclic flavone derivatives, such as those described by formula provided herein, pharmaceutical compositions, and methods related thereto. In certain embodiments, the disclosure relates to methods of treating or preventing diseases or conditions related to BDNF and TrkB activity, such as depression, stroke, Rett syndrome, Parkinsons disease, and Alzheimers disease by administering effective amounts of pharmaceutical compositions comprising compounds disclosed herein.


Patent
Emory University and Georgia Institute of Technology | Date: 2017-06-21

Diagnostic devices; systems, methods and computer-readable media store instructions related to determining hemoglobin information using those devices. The methods may include processing a captured image of the reservoir and/or device and the device information to determine color information for the solution and the scale, the color information including one or more color attributes; adjusting the color information for the solution based on the color information for the scale; and determining hemoglobin information (e.g., hemoglobin level, disease state and/or calculated hematocrit) based on the adjusted color information and a stored profile information associated with the device information.


The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a biguanide compound, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.

Loading Emory University collaborators
Loading Emory University collaborators